The potential of circulating nucleic acids as components of companion diagnostics for predicting and monitoring chemotherapy response

Expert Review of Molecular Diagnostics

Volumn 15, Issue 2, 2015, Pages 267-275

  Schwarzenbach, Heidi ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

chemotherapy; circulating DNA; circulating miRNA; epigenetic alterations; genetic alterations; resistance; targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; MICRORNA; NUCLEIC ACID; TUMOR MARKER;

BIOPSY; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CIRCULATING TUMOR CELL; CIRCULATION; DNA DETERMINATION; EXOSOME; HUMAN; PREDICTION; REVIEW; RNA ANALYSIS; TUMOR BIOPSY; BLOOD; GENETIC EPIGENESIS; GENETICS; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PERSONALIZED MEDICINE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DNA, NEOPLASM; EPIGENESIS, GENETIC; HUMANS; INDIVIDUALIZED MEDICINE; MICRORNAS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84921358315     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2015.980817     Document Type: Review

References (68)

1. Duffy MJ. Role of tumor markers in patients with solid cancers: a critical review. Eur J Intern Med 2007;18(3):175-84
2. Philip R, Carrington L, Chan M. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics. Bioanalysis 2011;3(4):383-9
3. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11(6):426-37
4. Stroun M, Maurice P, Vasioukhin V, et al. The origin and mechanism of circulating DNA. Ann N Y Acad Sci 2000;906:161-8
5. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011;108(12):5003-8
6. Orozco AF, Lewis DE. Flow cytometric analysis of circulating microparticles in plasma. Cytometry A 2010;77(6):502-14
7. Schwarzenbach H, Nishida N, Calin GA, et al. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 2014;11(3):145-56
8. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136(2): 215-33
9. Angulo B, Lopez-Rios F, Gonzalez D. A new generation of companion diagnostics: cobas BRAF, KRAS and EGFR mutation detection tests. Expert Rev Mol Diagn 2014;14(5):517-24
10. Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005; 102(45):16368-73
11. Cooke S, Campbell P. Circulating DNA and next-generation sequencing. Recent Results Cancer Res Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2012;195:143-9
12. Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013;497(7447):108-12
13. Pinto JL, Fonseca FL, Marsicano SR, et al. Systemic chemotherapy-induced microsatellite instability in the mononuclear cell fraction of women with breast cancer can be reproduced in vitro and abrogated by amifostine. J Pharm Pharmacol 2010;62(7): 931-4
14. Maier J, Lange T, Kerle I, et al. Detection of mutant free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor harboring activating mutations of CKIT or PDGFRA. Clin Cancer Res 2013;19(17):4854-67
15. Spindler KL, Pallisgaard N, Andersen RF, et al. Gemcitabine and capecitabine for heavily pre-Treated metastatic colorectal cancer patients a phase II and translational research study. Anticancer Res 2014;34(2): 845-50
16. Spindler KL, Pallisgaard N, Andersen RF, et al. Changes in mutational status during third-line treatment for metastatic colorectal cancer-Results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int J Cancer 2014;135(9):2215-22
17. Sakai K, Horiike A, Irwin DL, et al. Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Sci 2013;104(9):1198-204
18. Nakamura T, Sueoka-Aragane N, Iwanaga K, et al. A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA. J Thorac Oncol 2011; 6(10):1639-48
19. Yam I, Lam DC, Chan K, et al. EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients. J Thorac Oncol 2012;7(7):1131-40
20. Mack PC, Holland WS, Burich RA, et al. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-Treated non-small cell lung cancer. J Thorac Oncol 2009;4(12):1466-72
21. Kuang Y, Rogers A, Yeap BY, et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer 2009;15(8):2630-6
22. Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer 2014;20(6):1698-705
23. Wang S, An T, Wang J, et al. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Clin Cancer Res 2010;16(4):1324-30
24. Salkeni MA, Zarzour A, Ansay TY, et al. Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients. J Neurooncol 2013;115(1):27-35
25. Sharma G, Mirza S, Parshad R, et al. DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients. Tumour Biol 2012;33(6):1837-43
26. Chen KG, Sikic BI. Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res 2012; 18(7):1863-9
27. Sharma G, Mirza S, Parshad R, et al. CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin Biochem 2010; 43(4-5):373-9
28. Ramirez JL, Salazar MF, Gupta J, et al. Methylation patterns and chemosensitivity in NSCLC. Adv Exp Med Biol 2006;587: 195-209
29. Fiegl H, Millinger S, Mueller-Holzner E, et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 2005;65(4):1141-5
30. Gifford G, Paul J, Vasey PA, et al. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004;10(13):4420-6
31. Kong W, Yang H, He L, et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 2008;28(22):6773-84
32. Sun Y, Wang M, Lin G, et al. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One 2012;7(10):e47003
33. Chen J, Wang W, Zhang Y, et al. Predicting distant metastasis and chemoresistance using plasma miRNAs. Med Oncol 2014;31(1):799
34. Muller V, Gade S, Steinbach B, et al. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat 2014;147(1):61-8
35. Wang H, Tan G, Dong L, et al. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 2012;7(4):e34210
36. Cui EH, Li HJ, Hua F, et al. Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy. Acta Pharmacol Sin 2013; 34(2):309-13
37. Freres P, Josse C, Bovy N, et al. Neoadjuvant chemotherapy in breast cancer patients induces miR-34a and miR-122 expression. J Cell Physiol 2014. [Epub ahead of print]
38. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266(5186):807-10
39. Tazawa H, Tsuchiya N, Izumiya M, et al. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA 2007;104(39):15472-7
40. Zhang J, Zhang K, Bi M, et al. Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. Anticancer Drugs 2014;25(3):346-52
41. Ohyashiki K, Umezu T, Yoshizawa S, et al. Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma. PLoS One 2011;6(2):e16408
42. Huang Y, Yang YB, Zhang XH, et al. MicroRNA-21 gene and cancer. Med Oncol 2013;30(1):376
43. Liu R, Chen X, Du Y, et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 2012;58(3):610-18
44. Wang P, Zhuang L, Zhang J, et al. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Mol Oncol 2013;7(3):334-45
45. Lin HM, Castillo L, Mahon KL, et al. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer 2014;110(10):2462-71
46. Summerer I, Niyazi M, Unger K, et al. Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients. Radiat Oncol 2013;8:296
47. Tanaka K, Miyata H, Yamasaki M, et al. Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. Ann Surg Oncol 2013;20(Suppl 3): S607-15
48. Ji J, Yu L, Yu Z, et al. Development of a miR-26 companion diagnostic test for adjuvant interferon-Alpha therapy in hepatocellular carcinoma. Int J Biol Sci 2013;9(3):303-12
49. Shi MM. Technologies for individual genotyping: detection of genetic polymorphisms in drug targets and disease genes. Am J Pharmacogenomics 2002;2(3): 197-205
50. Hindson BJ, Ness KD, Masquelier DA, et al. High-Throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 2011; 83(22):8604-10
51. Wittenberger T, Sleigh S, Reisel D, et al. DNA methylation markers for early detection of women's cancer: promise and challenges. Epigenomics 2014;6(3):311-27
52. Chen C, Ridzon DA, Broomer AJ, et al. Real-Time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005;33(20):e179
53. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet 2012;13(5): 358-69
54. Dong H, Lei J, Ding L, et al. MicroRNA: function, detection, and bioanalysis. Chem Rev
55. Kukita Y, Uchida J, Oba S, et al. Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data. PLoS One 2013;8(11): e81468
56. Baudhuin LM, Donato LJ, Uphoff TS. How novel molecular diagnostic technologies and biomarkers are revolutionizing genetic testing and patient care. Expert Rev Mol Diagn 2012;12(1): 25-37
57. Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol 2008; 26(10):1135-45
58. Hafner M, Renwick N, Brown M, et al. RNA-ligase-dependent biases in miRNA representation in deep-sequenced small RNA cDNA libraries. RNA 2011; 17(9):1697-712
59. Joosse SA, Pantel K. Biologic challenges in the detection of circulating tumor cells. Cancer Res 2013;73(1):8-11
60. van de Stolpe A, den Toonder JM. Circulating tumor cells: what is in it for the patient?. A vision towards the future. Cancers 2014;6(2):1195-207
61. Garcia-Olmo D, Garcia-Olmo DC. Functionality of circulating DNA: the hypothesis of genometastasis. Ann N Y Acad Sci 2001;945:265-75
62. Garcia-Olmo DC, Picazo MG, Garcia-Olmo D. Transformation of non-Tumor host cells during tumor progression: theories and evidence. Expert Opin Biol Ther 2012;12(Suppl 1):S199-207
63. Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev 2013;32(3-4):623-42
64. Mandel P, Métais P. Les acides nucléiques du plasma sanguin chez l'homme. C R Acad Sci Paris 1948;142:241-3
65. Swarup V, Rajeswari MR. Circulating (cellfree) nucleic acids-A promising, non-invasive tool for early detection of several human diseases. FEBS Lett 2007;581(5):795-9
66. Vlassov VV, Laktionov PP, Rykova EY. Extracellular nucleic acids. Bioessays 2007; 29(7):654-67
67. Schwarzenbach H. Circulating nucleic acids and protease activities in blood of tumor patients. Expert Opin Biol Ther 2012; 12(Suppl 1):S163-9
68. Chiu RW, Lo YM. Clinical applications of maternal plasma fetal DNA analysis: translating the fruits of 15 years of research. Clin Chem Lab Med 2013;51(1):197-204